Company / Accounts Receivable
Caribou Biosciences, Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$69.0K
FY2025
5-year range
$69.0K / $1.2M
FY2021-FY2025
Trend
-74.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $148,000 to $69,000 over the past 2 years.
Based on SEC 10-K filings.
$69,000 in FY2025 with a 3-year CAGR of -30.1%.
Declined from $148,000 to $69,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -30.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -30.1%, indicating a declining trend.
- In FY2025, accounts receivable decreased 74.0% year-over-year.
- Peak accounts receivable was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $69.0K | -74.0% |
| FY2024 | $265.0K | +79.1% |
| FY2023 | $148.0K | -26.7% |
| FY2022 | $202.0K | -82.5% |
| FY2021 | $1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026